Less than a year after Rhopressa launch, Aerie scores new glaucoma drug approval
Just over a year after securing approval for its glaucoma drug, Rhopressa, Aerie Pharmaceuticals has followed up with an approval for its second such treatment engineered to tackle hard-to-treat cases of the common eye disease that if untreated typically culminates in blindness.
The new approval, granted by the FDA on Tuesday, is for Rocklatan — a once daily eye drop comprising the widely used generic latanoprost and netarsudil, the active ingredient in Rhopressa.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.